These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9515805)

  • 1. Elucidation of the mechanism enabling tumor selective prodrug monotherapy.
    Bosslet K; Straub R; Blumrich M; Czech J; Gerken M; Sperker B; Kroemer HK; Gesson JP; Koch M; Monneret C
    Cancer Res; 1998 Mar; 58(6):1195-201. PubMed ID: 9515805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site.
    Mürdter TE; Sperker B; Kivistö KT; McClellan M; Fritz P; Friedel G; Linder A; Bosslet K; Toomes H; Dierkesmann R; Kroemer HK
    Cancer Res; 1997 Jun; 57(12):2440-5. PubMed ID: 9192823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-selective prodrug activation by fusion protein-mediated catalysis.
    Bosslet K; Czech J; Hoffmann D
    Cancer Res; 1994 Apr; 54(8):2151-9. PubMed ID: 8174122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of three approaches to doxorubicin therapy: free doxorubicin, liposomal doxorubicin, and beta-glucuronidase-activated prodrug (HMR 1826).
    Woessner R; An Z; Li X; Hoffman RM; Dix R; Bitonti A
    Anticancer Res; 2000; 20(4):2289-96. PubMed ID: 10953287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell surface display of a lysosomal enzyme for extracellular gene-directed enzyme prodrug therapy.
    Heine D; Müller R; Brüsselbach S
    Gene Ther; 2001 Jul; 8(13):1005-10. PubMed ID: 11438835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer.
    Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Br J Cancer; 2001 Feb; 84(4):550-7. PubMed ID: 11207053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose optimization of a doxorubicin prodrug (HMR 1826) in isolated perfused human lungs: low tumor pH promotes prodrug activation by beta-glucuronidase.
    Mürdter TE; Friedel G; Backman JT; McClellan M; Schick M; Gerken M; Bosslet K; Fritz P; Toomes H; Kroemer HK; Sperker B
    J Pharmacol Exp Ther; 2002 Apr; 301(1):223-8. PubMed ID: 11907177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy.
    Fonseca MJ; Storm G; Hennink WE; Gerritsen WR; Haisma HJ
    J Gene Med; 1999; 1(6):407-14. PubMed ID: 10753066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
    Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
    Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.
    Wong BK; DeFeo-Jones D; Jones RE; Garsky VM; Feng DM; Oliff A; Chiba M; Ellis JD; Lin JH
    Drug Metab Dispos; 2001 Mar; 29(3):313-8. PubMed ID: 11181501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy.
    de Graaf M; Nevalainen TJ; Scheeren HW; Pinedo HM; Haisma HJ; Boven E
    Biochem Pharmacol; 2004 Dec; 68(11):2273-81. PubMed ID: 15498517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
    Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin.
    Ravel D; Dubois V; Quinonero J; Meyer-Losic F; Delord J; Rochaix P; Nicolazzi C; Ribes F; Mazerolles C; Assouly E; Vialatte K; Hor I; Kearsey J; Trouet A
    Clin Cancer Res; 2008 Feb; 14(4):1258-65. PubMed ID: 18281561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
    Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
    Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
    Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
    Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regressions and cures of melanoma xenografts following treatment with monoclonal antibody beta-lactamase conjugates in combination with anticancer prodrugs.
    Kerr DE; Schreiber GJ; Vrudhula VM; Svensson HP; Hellström I; Hellström KE; Senter PD
    Cancer Res; 1995 Aug; 55(16):3558-63. PubMed ID: 7627964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies.
    Trouet A; Passioukov A; Van derpoorten K; Fernandez AM; Abarca-Quinones J; Baurain R; Lobl TJ; Oliyai C; Shochat D; Dubois V
    Cancer Res; 2001 Apr; 61(7):2843-6. PubMed ID: 11306455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
    Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
    Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
    Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
    J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
    Sugano M; Egilmez NK; Yokota SJ; Chen FA; Harding J; Huang SK; Bankert RB
    Cancer Res; 2000 Dec; 60(24):6942-9. PubMed ID: 11156394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.